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Australia’s medical marijuana 
subterfuge
Gary Christian
Research Director, Drug Free Australia, Central Coast, NSW
It is a little known fact that medical cannabis 
has been legally available on prescription 
from General Practitioners for more than 18 
years in Australia. The curious media calls 
to ‘legalise’ an already legal medication has 
generated the illusion that medical cannabis 
has always been as illegal as its recreational 
use, and that State and Federal Governments 
really do need to make the legality of medical 
cannabis a reality. So why has the Australian 
media almost uniformly been keeping the 
Australian public in the dark about the already 
legal status of medical cannabis, and why has 
it campaigned so strongly and deceptively 
about something we have long had, albeit rarely 
used? This discussion informs educators and 
potentially their students, particularly in areas 
within current personal development and health 
curricula.
Some background
Back in 1999, a NSW parliamentary briefing 
paper (Griffith & Swain) noted that in 1997 general 
practitioners were prescribing the pill Marinol for 100 
patients in NSW under the Australian Therapeutic 
Goods Administration (TGA) Special Access 
Scheme. Marinol, otherwise called Dronabinol, is 
a synthetic form of the psychoactive constituent 
in cannabis, tetrahydrocannabinol, the chemical 
properties of which were isolated and then 
reproduced when Marinol first entered the market in 
1985. The therapeutic effect of Marinol lasts twice 
as long as smoked cannabis with the same ‘high’ but 
also exhibits the same negative side-effects such as 
dizziness, anxiety and confusion (Cooper, Comer, & 
Haney, 2013).
In 2012, a cannabis whole-plant extract, Sativex, 
was registered with the TGA for use by Multiple 
Sclerosis patients in the form of an oral spray. 
Sativex was stocked by Australian pharmacies for 
a short time before being withdrawn due to lack 
of interest by patients. Nevertheless the TGA has 
confirmed in writing (Drug Free Australia, 2015) 
that GPs are able, under their Special Access 
Scheme, to prescribe Sativex, as with Marinol, 
for patients with a variety of other conditions that 
might be alleviated by cannabis. Internet-purchased 
Sativex can be imported legally into Australia with 
a permit so long as it has been prescribed. These 
confirmations from the TGA have been described 
and sent in multiple letters and opinion pieces by 
Drug Free Australia, the country’s peak prevention 
body, to each of the major press, radio and television 
outlets throughout Australia to correct their false 
understanding. None have ever responded or 
changed their rhetoric.
Medical indications for cannabis
Many claims have been made by cannabis users 
about the benefits of cannabis medicinally, but the 
majority of these claims have evaporated under 
the scrutiny of clinical trials. Because cannabis has 
a well-documented withdrawal syndrome, many 
of these claims only address the effectiveness of 
cannabis in alleviating its own withdrawal symptoms 
– pain, muscle spasm, agitation, fits, convulsions
and rheumatics are the most common (Reece, 2014). 
This is important because many of the patients 
who present public testimony before Parliamentary 
inquiries are speaking from a background of prior 
cannabis dependency and addiction.
Rigorous clinical trials have isolated a number 
of conditions where actual benefit has been 
demonstrated. In terms of chronic pain, where 
cannabis has a mild analgesic effect comparable in 
strength to codeine, it can become a useful adjunct 
for those who don’t tolerate opiates well. Cannabis 
can alleviate some symptoms of MS, reduce 
nausea and vomiting, and reduce AIDS wasting by 
increasing appetite in patients (Institute of Medicine, 
1999). For each of these conditions there are more 
effective medications available to doctors, and 
so medical cannabinoids do not in any of these 
conditions represent a first-line treatment, or second 
or third for that matter, available to doctors (Reece, 
2014). Consequently, it is revealing that the calls 
for medical cannabis have not been coming from 
doctors or their medical associations, but rather from 
people with an entirely different agenda.
In 2014, significant publicity was given to the 
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effect of cannabis on Dravet’s and Lennox-Gastaut’s 
syndromes, which both cause severe epilepsy-
like seizures particularly in young children. Some 
children have been helped by the use of cannabis 
strains high in Cannabidiol (CBD), a constituent of 
cannabis which is not psychoactive as is THC. The 
manufacturer of Sativex, GW Pharmaceuticals, has 
completed third stage clinical trials of Epidiolex, 
which like Marinol and Sativex is a pharmaceutical-
quality medication with standardised dosage, 
strength and purity, but with high levels of CBD. 
Epidiolex is available in the USA for trials, (Epilepsy, 
Australia, 2014) and the Federal Government 
announced in February 2016 that it will commence 
trials of Epidiolex in Australia shortly (Beech, 
2016). This scraps the NSW Government’s plans to 
produce their own similar preparation in NSW.
Media agenda? Most likely recreational use
So why was the media, along with the ACT and 
Victorian Governments, continuing to call for medical 
cannabis to be legalised when it was already legal? 
The answer is very simple. In the USA, where 
States hold referenda on various legislative issues 
at the time of each federal election, the cannabis 
legalisation lobby has had a fighting-fund spend that 
is 25 times greater than the anti-cannabis lobby, as 
disclosed in a November 2012 meeting I had with Gil 
Kerlikowske, the US drug Czar at NSW’s Parliament 
House. Some of the world’s richest men such as 
George Soros, who spends up to half a billion dollars 
yearly on his social liberalism agendas, heavily fund 
these referenda on legalising cannabis, first for 
medical purposes and then for outright recreational 
use as has now happened in a number of US States. 
The massive spend on repeated TV advertising 
shows sick people claiming in-camera their dire 
need to access medical marijuana. Despite many 
of these televised conditions not being supported 
by any objective evidence, more than 20 States 
have voted to legalise medical marijuana, many with 
home-grown cannabis legally available to patients.
Ruse of recreational use
What the US public is not told, nor has the 
prevention lobby the money to tell them with any 
penetration, is that 95% of medical marijuana 
‘patients’ are previous recreational users. Surveys 
by the US Institute of Medicine in the late 1990s had 
found as much (Institute of Medicine, 1999). Nor 
are they told that cannabis has only a handful of 
conditions it alleviates, and almost all of these have 
far more effective medications available. The public 
is not told that cannabis actually causes the chronic 
back pain which many claim cannabis alleviates, 
quite clearly as part of its own withdrawal syndrome, 
along with other conditions arising from its use which 
cannabis will always appear to alleviate.  
Effectively, US States have allowed popular 
vote to determine what is a medicine based on 
emotive advertising, rather than the normal scientific 
regulatory processes applied to every other available 
medicine. Predictably, there are tens of thousands in 
each corresponding US State citing conditions they 
claim cannabis alleviates, however, in the early years 
of Nevada’s legislation, 93% of the maladies claimed 
were severe pain (53%), muscle spasm (29%) and 
severe nausea (11%) (Gogek, 2015) which cannot 
be objectively verified by a doctor and must be 
accepted on faith. The Australian Disability Support 
Pension constantly faces many similar health claims 
which are just as unverifiable, many of which are 
exposed in the media as false.
Medical cannabis has, in many of those US 
States which have poorly framed medical cannabis 
laws, become the route to ‘legalised’ recreational 
use (Gogek, 2015). Colorado introduced medical 
cannabis laws in 2001, and by 2004 had just 512 
patients accessing raw cannabis leaf, which is 
available in that state for smoking or ingestion. By 
2010 the number had exponentially grown to more 
than 100,000 according to data from Colorado’s 
Department of Public Health and environment, with 
94% registered for the unverifiable condition, pain.  
Oregon has 94% claiming pain while Arizona has 
90%.
Pain profiles and pain management
There are well established profiles for patients of 
chronic pain across all Western countries, where 
patients are more predominantly women and those 
aged 60 and above. For instance, a 2001 study by 
Sydney University’s Pain Management Research 
Centre (Blythe et al., cited in Access Economics, 
2002) found 54% of patients were women (p. 15), 
with men suffering in their sixties and women in 
their eighties (p. 12). Yet the profile for pain patients 
using medical cannabis in the USA is very different. 
A 2007 study of 4,000 medical cannabis patients in 
California (Gogek, 2015), found that their average 
age was 32, 75% were male and 90% had started 
using cannabis while teenagers, an identical age 
and gender profile to that of recreational users 
across the US. This discordant profile means that 
medical cannabis in the various states of the US has 
mainly amounted to a quasi-legalisation strategy 
for recreational use of cannabis via subterfuge and 
ruse.
Approving recreational use of a drug?
It is no surprise then that the full legalisation of 
cannabis for recreational use has followed in six 
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poppy crop in 
Tasmania
US States or jurisdictions since the introduction 
of medical cannabis laws. Pot activists are now 
agitating for legalisation of recreational use in 
every State. Such legalisation is in open breach of 
the United Nations’ Single Convention on Narcotic 
Drugs which applies to every country world-wide, but 
President Obama and Presidential hopeful, Hillary 
Clinton, are too compromised to intervene federally 
– the aforementioned George Soros is the largest
financial backer of the Democrats.
A contemporary Australian issue
In Australia, where no similar referendums are held, 
the pathway to legalisation is not so easily bought.  
Shaping opinion
In 2012, the Australia21 forum, (Douglas & 
McDonald, 2012) with influential Australians such 
as former NSW Premier Bob Carr and former NSW 
Director of Public Prosecutions Nicholas Cowdery, 
began agitating in the media for the legalisation of 
all drugs – heroin, cocaine, speed, ice, ecstasy and 
cannabis – with the televised media giving them 
plenty of airplay, albeit fairly with Drug Free Australia 
brought in to debate the issue on air.  By contrast 
the Sydney Morning Herald held a public debate 
at Sydney University where five drug legalisation 
advocates were pitted against a single prevention 
advocate. Not one contrary opinion was reproduced 
in any print media Australia-wide, including in 
Murdoch papers such as The Australian or the Daily 
Telegraph, which usually represent the conservative 
voice within Australia.
By 2013, with that push gaining no traction with 
the public, Australia21 operatives looked for a new 
pathway to legalising drugs, and found it in a young 
NSW cancer patient from Tamworth, Dan Haslam 
(Knott, 2014), who publicised his need to smoke 
cannabis to alleviate chemotherapy-induced nausea. 
And it is precisely this that the media is fighting 
for—not for medical cannabis per se, which is clearly 
already legal, but for crude non-pharmaceutical 
cannabis products which they hope will not be 
regulated by the TGA, all for the end-game, it would 
seem, of getting home-grown cannabis made 
available to all as it is in many US States. 
Government initiatives - legislative action
In the ACT in late 2014, the Greens Bill (ACT 
Government, 2014) to legalise medical cannabis 
specifically stated that Sativex was not part of 
their plan, despite Sativex delivering all the same 
cannabinoids via a safer and faster-acting delivery 
system than hash cookies, bongs or crude cannabis 
oils. Their Bill sought to legalise home-grown 
cannabis, with up to nine cannabis plants being 
considered a non-trafficable quantity. What they 
failed to tell the public was that a single cannabis 
plant can produce 5 crops a year with a total 2,500 
grams, enough to make 8,600 joints (Drug Free 
Australia, 2015). With the average medical cannabis 
patient in the US requiring 1.5 grams per day or 550 
grams per year, a single plant provides five times the 
needed quantity, which in the US has provided too 
much temptation for patients who could use extra 
cash. Nine cannabis plants, as proposed by the 
Greens Bill, could have produced a street value of 
$270,000 worth of cannabis per year per individual 
– a nice little earner. The Bill was defeated (McElroy,
2015), a victory for common sense.
The current position
In February 2016 Federal Health Minister Sussan 
Ley announced legislation (Beech, 2016) allowing 
cannabis to be grown in Australia for medical use 
under strict cultivation conditions similar to the opium 
poppy crop in Tasmania (Yaxley, 2015). A centralised 
regulator controlled by the strictures of the Australian 
TGA would oversee the entire production of 
medical cannabis products which would be only 
pharmaceutical products. No raw cannabis products 
would be available for smoking or ingestion. This 
undermines the pathway to legalising recreational 
use. As it is, the legislation is a concession to pot 
activists in that it is only pegged to TGA strictures, 
not directly under the control of the TGA, which will 
more easily allow political tampering in the future.
Costings and consequences
In late 2015 Ley had suggested much lower costs of 
producing cannabis oils under this regulator, claiming 
that Australia might produce medical cannabis 
pharmaceuticals cheaper than those already available 
from overseas. She particularly mentioned that they 
could be made available in the form of tinctures or 
oils. What Ley may not have realised is that home-
made cannabis oils can attain THC concentrations of 
80% (High Times, 2014) as compared to 3% in bush-
grown smoked cannabis. This could promote extreme 
cannabis intoxication. It was surmised that Australian 
pot activists may be seeing oils as their product of 
choice for use in e-cigarettes (Greig, 2013) where 
tobacco or cannabis oil is vaporised and publicly 
‘smoked’ with no odour to allow detection by police. 
Drug Free Australia called for legislative measures to 
close down this pathway to recreational use via the 
medical cannabis ticket and pain alibi.
It is doubtful that Australia can reduce the cost of 
pharmaceutical cannabis medications substantially. 
As it is, the cost to medical cannabis users of illegal 
cannabis purchased on a street corner, at an average 
$12.00 a gram or $500 per month, is exactly the same 
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cost as cannabis bought from commercial growers 
by patients in the USA, as verified in a submission 
by cannabis legalisation organisation NORML (2009) 
to an Obama Inquiry. The UK-produced Sativex also 
costs patients $500 per month (NSW Legislative 
Council, 2013). Oddly enough, NSW Premier 
Baird’s plan to produce cheaper pharmaceutical 
cannabinoids led to advertising for local expertise 
to develop a CBD-rich medication for children with 
epilepsy-like seizures, as disclosed in a January 
2015 Drug Free Australia meeting with NSW Health 
Minister. It resulted in the Government announcing 
trials with Epidiolex purchased from the UK (News 
Limited, 2015).
Visioning our future
Present indications are that the Federal legislation 
will avoid many of the problems besetting the US 
legislations. There is a high price to be paid for having 
lax medical marijuana laws – the deleterious effect 
it has particularly on the young people for whom 
cannabis, as with alcohol, could never be legalised. 
In Colorado, which has allowed six plants per patient 
since 2009, 74% of teenagers surveyed entering 
rehabilitation for cannabis addiction reported that they 
sourced cannabis from medical marijuana patients 
(Salomonsen-Sautel, Sakai, Thurstone, Corley, & 
Hopfer, 2012). This issue of diversion of cannabis 
to minors for recreational use has been the most 
dangerous aspect of the push for crude cannabis, 
considering the damage done to any teenager’s 
developing brain. A recent Lancet study (Di Forti et 
al., 2015) found that daily users of strong forms of 
cannabis have a five times greater risk of developing 
psychoses, many of which will debilitate them for life.
Public opinion on drug use
Australians do not want drug use entrenched in this 
country for 98% of the 24,000 people surveyed in the 
2013 National Drug Strategy Household Survey did 
not approve the use of heroin, ecstasy, speed, ice 
and cocaine, 90% did not approve the regular use 
of cannabis, and 74% of Australians did not want to 
legalise cannabis. Further, 93% or more, depending 
on which drug is considered, did not want to legalise 
the other illicits. But persistently, a group working 
since 1992 has sought to change Australia’s drug 
laws, seeing the choice to use any drug as a human 
right. It is a ‘right’ that doesn’t exist because there is 
worldwide agreement that the harms presented by 
illegal drugs are unacceptable. That hasn’t stopped 
the drug law reformers.
Challenging legalisation advocacy
The chosen pathway to a final goal of drug 
legalisation has been via harm reduction 
interventions, which presuppose an acceptance of 
illicit drug use with free needle programs, methadone 
maintenance and injecting rooms. The President 
of the Australian Drug Law Reform Foundation—
Australia’s drug legalisation movement—is also 
lauded as the father of harm reduction in Australia 
(Wodak, 2012), having formally set up the first 
needle exchange as an act of civil disobedience 
in the mid 1980s. In a speech reproduced in the 
Australian Drug Law Reform Foundation newsletter 
he (Wodak, 2005, para. 1.) stated that, “it is time 
to move from the first phase of harm reduction – 
focusing on removing adverse consequences – to 
a second phase which concentrates on reforming 
an ineffective and harm generating system of global 
drug prohibition.” As a leading member of the 
Australia21 group, and the most vocal advocate for 
Dan Haslam’s right to smoke cannabis as a cancer 
sufferer, his stated aims give a clear picture of what 
was behind the push for non-pharmaceutical forms 
of medical cannabis. For them, the acceptance 
of medical cannabis will ultimately lead to an 
acceptance of recreational use.
In 2012 almost all Australian media outlets gave 
Australia21 a platform to declare that the ‘war on 
drugs’ had failed and it was time to scrap prohibition. 
At that time, prevention organisations responded by 
asking, “What war on drugs?” (Channel 7 Sunday 
Sunrise, 2012). When Australia has done everything 
to pander to drug users by handing them free 
needles, maintaining drug users on methadone for 
up to 40 years, and giving them injecting rooms, this 
cannot be construed as a war on drugs. For 28 years 
now we have been facilitating drug use, anything 
but a war. And if we want to call the regular policing 
of drug use a ‘war on drugs’ why think it has failed?  
We don’t abandon our ‘war’ on stealing, speeding 
or rape because we know we can never eradicate 
them, but we always seek to control them because if 
we don’t the societal harms are catastrophic.
Maintain the ‘war’
In 1998 the Howard government implemented the 
Tough on Drugs strategy, which maintained the 
harm reduction strategies that continue to facilitate 
drug use, but introduced a new and stronger 
prevention emphasis. Between 1998 and 2007 
heroin use reduced by 75%, speed and ice use 
by 40% and cannabis use by 50%. While cocaine 
use rose by 15% and ecstasy use by a worrying 
46%, assessment suggests successes outweighed 
failures (Australian Institute of Health and Welfare, 
2011).
A comparison of the legal drugs, alcohol and 
tobacco, with the illegal drugs shows the success of 
prohibition. Alcohol is used by 81% of Australians, 
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of the USA, 
a path … 
compassionate 
but sensible
while tobacco in its heyday was used by 65% of 
Australians. It has taken many years and millions 
of dollars to reduce tobacco use in Australia. 
By comparison the illicits are a fraction of those 
percentages - opiates are used by 0.5%, cocaine 
by 2%, amphetamines by 2%, ecstasy by 2.5% and 
cannabis by 10%.  
It is clear that Australians want less drug use, not 
more. Legalisation of drugs will only add significant 
use. Medical cannabis as the media was promoting 
it, would definitely have added more. Australia is 
taking a path which has learned from the mistakes 
of the USA, a path which is compassionate but 
sensible.
Educators are encouraged to lead their students 
in discussions considering the social influences 
affecting wellbeing, as required by the PDHPE 
curriculum of NSW or its equivalent in other states, 
but in particular to address the impact of pressure 
groups influencing legislative processes providing 
for, and protecting health. The current promotion of 
a medical use of marijuana provides a useful case 
study within which the complexity of community 
interaction becomes apparent. It highlights both the 
importance and difficulty of maintaining an open, 
clearly informed, research based decision-making 
political process. TEACH
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